Donepezil Shows Promise for Severe Alzheimer’s

In a study released last week published in the Journal of the American Academy of Neurology, the drug donepezil has improved the cognitive functioning and memory of individuals with severe Alzheimer’s disease.

The study, funded by Eisai Inc. and Pfizer, makers of the drug, took place over six months and studied 343 individuals.Half of the group took donepezil and the other half received a placebo.

The results showed that over 63% of the individuals demonstrated memory stabilization or increased function, compared to 39% on the placebo.